Summer Sale
50% off Premium Yearly
00days
00hrs
00mins
00secs
Opinions David Driscoll
Bayer AGBAYRYDON'T BUYDec 07, 2018
Their last quarter wasn't great; there was some positive news in their pharma pipeline. They sold assets from BASF to reduce net debt, which is now at Euros 36.5 billion. The debt-to-cash flow is still high, so they have a low credit rating. Their chemical side isn't growing. EPS are down 18%, which pressured the stock. JNJ has a better phrama pipeline and credit rating.
David DriscollUnknown
N/A
Stock price when the opinion was issued
$10.56
As of Jun 18, 2026. Market Open.
chemicals
It's the ideal tool to help you make quicker, more informed decisions for managing and tracking your investments.
You might be interested:
TOP PICK
It is priced at 50 cents on the dollar compared to its peers. In 2018 it bought Monsanto and the Roundup litigation halved the company. However it is being dealt with. It has three new drugs on the pharma side, one with no near term competitors when it comes off patent. It will probably spin out the herbicide business and sits at a very attractive price. Buy 18 Hold 8 Sell 1
Darren SissonsOwned
chemicals
DON'T BUY
Into pharmaceuticals and chemicals. Things seem to be moving along very well. Getting a little overpriced at these levels.
Don ReedOwned
chemicals
